ADPT Strangle Strategy
ADPT (Adaptive Biotechnologies Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.
ADPT (Adaptive Biotechnologies Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.10B, a beta of 2.16 versus the broader market, a 52-week range of 8.5-20.76, average daily share volume of 1.9M, a public-listing history dating back to 2019, approximately 619 full-time employees. These structural characteristics shape how ADPT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.16 indicates ADPT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on ADPT?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ADPT snapshot
As of May 15, 2026, spot at $12.96, ATM IV 129.90%, IV rank 25.26%, expected move 37.24%. The strangle on ADPT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ADPT specifically: ADPT IV at 129.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a ADPT strangle, with a market-implied 1-standard-deviation move of approximately 37.24% (roughly $4.83 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ADPT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ADPT should anchor to the underlying notional of $12.96 per share and to the trader's directional view on ADPT stock.
ADPT strangle setup
The ADPT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ADPT near $12.96, the first option leg uses a $13.61 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ADPT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ADPT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $13.61 | N/A |
| Buy 1 | Put | $12.31 | N/A |
ADPT strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ADPT strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ADPT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ADPT
Strangles on ADPT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ADPT chain.
ADPT thesis for this strangle
The market-implied 1-standard-deviation range for ADPT extends from approximately $8.13 on the downside to $17.79 on the upside. A ADPT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ADPT IV rank near 25.26% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ADPT at 129.90%. As a Healthcare name, ADPT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ADPT-specific events.
ADPT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ADPT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ADPT alongside the broader basket even when ADPT-specific fundamentals are unchanged. Always rebuild the position from current ADPT chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ADPT?
- A strangle on ADPT is the strangle strategy applied to ADPT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ADPT stock trading near $12.96, the strikes shown on this page are snapped to the nearest listed ADPT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ADPT strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ADPT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 129.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ADPT strangle?
- The breakeven for the ADPT strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ADPT market-implied 1-standard-deviation expected move is approximately 37.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ADPT?
- Strangles on ADPT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ADPT chain.
- How does current ADPT implied volatility affect this strangle?
- ADPT ATM IV is at 129.90% with IV rank near 25.26%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.